IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial
Most Cited Paper
in Dialysis and Renal Disease Management
18 Months Post-Publication
Class of 2026
“IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial”
A research intelligence initiative by Pepkio
pri.pepkio.com
Topics
clazakizumab · IL-6 · maintenance dialysis · high-sensitivity C-reactive protein · cardiovascular disease · diabetes · monoclonal antibody · IL-6 · phase 2b dose-finding study · serum fibrinogen · amyloid A · secretory phospholipase A2 · lipoprotein(a) · serum albumin · thrombocytopenia · neutropenia · serious infections · inflammatory biomarkers · cardiovascular risk
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Dialysis and Renal Disease Management Papers, Class of 2026. https://pri.pepkio.com/top-papers/dialysis-and-renal-disease-management/2026. Accessed 2026-08-20. Methodology Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459